Status:

COMPLETED

NGLY1 Natural History

Lead Sponsor:

Baylor College of Medicine

Collaborating Sponsors:

Grace Science Foundation

Conditions:

NGLY1 Deficiency

Eligibility:

All Genders

2-25 years

Brief Summary

N-glycanase 1 (NGLY1) Deficiency (OMIM #615273) is an ultra-rare, autosomal recessive disorder caused by loss of function variants in NGLY1 gene. The multisystemic disorder is characterized by five ke...

Detailed Description

This is a single center, longitudinal descriptive study of the concurrent movement disorders and neurodevelopmental and clinical status in children with NGLY1 Deficiency. Subjects will be recruited t...

Eligibility Criteria

Inclusion

  • \- Individuals aged 2 to 25 years with a confirmed molecular diagnosis of NGLY1 Deficiency.

Exclusion

  • \- Prior or current participation in a therapeutic trial for NGLY1 Deficiency (note that neither the plan for future participation in an interventional trial nor participation in previous pilot study preclude entering this trial).

Key Trial Info

Start Date :

February 27 2023

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 24 2024

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT06122766

Start Date

February 27 2023

End Date

October 24 2024

Last Update

April 11 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Texas Children's Hospital

Houston, Texas, United States, 77030